Literature DB >> 19956500

Intensity of tumor budding as an index for the malignant potential in invasive rectal carcinoma.

Sang-Sik Ha1, Hong-Jo Choi, Ki-Jae Park, Jung-Min Kim, Sung-Heun Kim, Young-Hoon Roh, Hyuk-Chan Kwon, Mee-Sook Roh.   

Abstract

PURPOSE: The aim of this study was to quantitatively assess the intensity of tumor budding in rectal carcinoma and to determine how it correlates with the malignant potential.
MATERIALS AND METHODS: Intensities of the tumor budding at the invasive front of the surgical specimens from 90 patients (male, 51) with well- or moderately-differentiated rectal carcinoma were investigated. Differences in the budding intensity among pathologic variables were compared, and recurrences and survivals were analyzed in accordance with degree of the budding intensity. The patients ranged in age from 33 to 75 years (mean, 55.4) with the median follow-up being 43 months (range, 12 approximately 108).
RESULTS: Tumor budding was identified in 89 patients (98.9%) with a mean intensity of 7.5+/-5.3. The budding intensity was significantly higher in tumors with lymphatic invasion (p=0.0081), blood vessel invasion (p<0.0001), and perineural invasion (p=0.0013) than in those tumor without these findings. It became significantly higher with the increase in nodal stage (p<0.0001). The intensity of tumor budding in patients with relapse (29 patients) was significantly higher than that in patients without relapse (6.2+/-5.0 vs. 10.2+/-4.9; p=0.0005), but this difference in the intensity was observed only for the node-positive patients (8.0+/-3.4 vs. 11.9+/-5.1; p=0.0064). When the patients were stratified into two groups on either side of the mean of the intensity, the higher intensity group showed a significantly less favorable disease-free (DFS) and overall survival (OS) (p=0.0026 and 0.0205, respectively). Based on the multivariate analysis, the nodal stage and the intensity of budding proved to be the independent variables associated with DFS (p=0.023 and 0.03, respectively).
CONCLUSION: Tumor budding at the invasive margin is a reliable pathologic index that indicates a higher malignant potential and a less favorable prognosis for patients with advanced rectal carcinoma.

Entities:  

Keywords:  Malignant potential; Rectal carcinoma; Tumor budding

Year:  2005        PMID: 19956500      PMCID: PMC2785407          DOI: 10.4143/crt.2005.37.3.177

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  21 in total

1.  Clinical implications of metastatic process.

Authors:  P Frost; B Levin
Journal:  Lancet       Date:  1992-06-13       Impact factor: 79.321

2.  Curative resection of T1 colorectal carcinoma: risk of lymph node metastasis and long-term prognosis.

Authors:  Huann-Sheng Wang; Wen-Yih Liang; Tzu-Chen Lin; Wei-Shone Chen; Jeng-Kae Jiang; Shung-Haur Yang; Shih-Ching Chang; Jen-Kou Lin
Journal:  Dis Colon Rectum       Date:  2005-06       Impact factor: 4.585

3.  Possible contribution of CD44 variant 6 and nuclear beta-catenin expression to the formation of budding tumor cells in patients with T1 colorectal carcinoma.

Authors:  T Masaki; A Goto; M Sugiyama; H Matsuoka; N Abe; A Sakamoto; Y Atomi
Journal:  Cancer       Date:  2001-11-15       Impact factor: 6.860

4.  Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer.

Authors:  H Ueno; J Murphy; J R Jass; H Mochizuki; I C Talbot
Journal:  Histopathology       Date:  2002-02       Impact factor: 5.087

5.  A new prognostic staging system for rectal cancer.

Authors:  Hideki Ueno; Ashley B Price; Kay H Wilkinson; Jeremy R Jass; Hidetaka Mochizuki; Ian C Talbot
Journal:  Ann Surg       Date:  2004-11       Impact factor: 12.969

6.  Budding as a useful prognostic marker in pT3 well- or moderately-differentiated rectal adenocarcinoma.

Authors:  Takashi Okuyama; Masatoshi Oya; Hiroshi Ishikawa
Journal:  J Surg Oncol       Date:  2003-05       Impact factor: 3.454

7.  Coexpression of matrilysin and laminin-5 gamma2 chain may contribute to tumor cell migration in colorectal carcinomas.

Authors:  Tadahiko Masaki; Masanori Sugiyama; Hiroyoshi Matsuoka; Nobutsugu Abe; Yumi Izumisato; Atsuhiko Sakamoto; Yutaka Atomi
Journal:  Dig Dis Sci       Date:  2003-07       Impact factor: 3.199

8.  Prognostic value of tumor "budding" in patients with colorectal cancer.

Authors:  K Hase; C Shatney; D Johnson; M Trollope; M Vierra
Journal:  Dis Colon Rectum       Date:  1993-07       Impact factor: 4.585

9.  Long-term results of curative resection of "minimally invasive" colorectal cancer.

Authors:  K Hase; C H Shatney; H Mochizuki; D L Johnson; S Tamakuma; M Vierra; M Trollope
Journal:  Dis Colon Rectum       Date:  1995-01       Impact factor: 4.585

10.  Carcinoembryonic antigen staining patterns at the invasive tumor margin predict the malignant potential of colorectal carcinoma.

Authors:  C R Teixeira; S Tanaka; K Haruma; M Yoshihara; K Sumii; G Kajiyama; F Shimamoto
Journal:  Oncology       Date:  1994 May-Jun       Impact factor: 2.935

View more
  8 in total

Review 1.  Tumour budding in colorectal cancer: what do we know and what can we do?

Authors:  Linde De Smedt; Sofie Palmans; Xavier Sagaert
Journal:  Virchows Arch       Date:  2015-11-27       Impact factor: 4.064

Review 2.  Tumour Budding and Survival in Stage II Colorectal Cancer: a Systematic Review and Pooled Analysis.

Authors:  F Petrelli; E Pezzica; M Cabiddu; A Coinu; K Borgonovo; M Ghilardi; V Lonati; D Corti; S Barni
Journal:  J Gastrointest Cancer       Date:  2015-09

3.  Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort.

Authors:  Rondell P Graham; Robert A Vierkant; Lori S Tillmans; Alice H Wang; Peter W Laird; Daniel J Weisenberger; Charles F Lynch; Amy J French; Susan L Slager; Yassaman Raissian; Joaquin J Garcia; Sarah E Kerr; Hee Eun Lee; Stephen N Thibodeau; James R Cerhan; Paul J Limburg; Thomas C Smyrk
Journal:  Am J Surg Pathol       Date:  2015-10       Impact factor: 6.394

Review 4.  Tumor Budding: The Name is EMT. Partial EMT.

Authors:  Alexandru Dan Grigore; Mohit Kumar Jolly; Dongya Jia; Mary C Farach-Carson; Herbert Levine
Journal:  J Clin Med       Date:  2016-04-29       Impact factor: 4.241

Review 5.  Tumor Budding, Micropapillary Pattern, and Polyploidy Giant Cancer Cells in Colorectal Cancer: Current Status and Future Prospects.

Authors:  Shiwu Zhang; Dan Zhang; Zhengduo Yang; Xipeng Zhang
Journal:  Stem Cells Int       Date:  2016-10-23       Impact factor: 5.443

6.  Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching.

Authors:  Linde De Smedt; Sofie Palmans; Daan Andel; Olivier Govaere; Bram Boeckx; Dominiek Smeets; Eva Galle; Jasper Wouters; David Barras; Madeleine Suffiotti; Jeroen Dekervel; Thomas Tousseyn; Gert De Hertogh; Hans Prenen; Sabine Tejpar; Diether Lambrechts; Xavier Sagaert
Journal:  Br J Cancer       Date:  2016-11-24       Impact factor: 7.640

Review 7.  RAS, Cellular Plasticity, and Tumor Budding in Colorectal Cancer.

Authors:  Valeria Maffeis; Lorenzo Nicolè; Rocco Cappellesso
Journal:  Front Oncol       Date:  2019-11-19       Impact factor: 6.244

8.  The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer.

Authors:  Hester C van Wyk; James H Park; Joanne Edwards; Paul G Horgan; Donald C McMillan; James J Going
Journal:  Br J Cancer       Date:  2016-06-14       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.